Cutler Group LP Vir Biotechnology, Inc. Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$18.26 - $31.1 $10,956 - $18,660	-600 Reduced 27.27%	1,600 $0
Q2 2022 Aug 04, 2022	SELL	$19.08 - $26.7 $78,228 - $109,470	-4,100 Reduced 65.08%	2,200 $2,000
Q1 2022 Apr 14, 2022	SELL	$21.19 - $40.01 $648,414 - $1.22 Million	-30,600 Reduced 82.93%	6,300 $1,000
Q4 2021 Jan 18, 2022	BUY	$30.97 - $54.03 $1.07 Million - $1.87 Million	34,600 Added 1504.35%	36,900 $19,000
Q2 2021 Jul 19, 2021	SELL	$38.75 - $51.0 $251,875 - $331,500	-6,500 Reduced 73.86%	2,300 $5,000
Q1 2021 Apr 26, 2021	BUY	$26.34 - $83.07 $36,876 - $116,297	1,400 Added 18.92%	8,800 $49,000
Q4 2020 Jan 21, 2021	BUY	$25.51 - $43.38 $127,550 - $216,900	5,000 Added 208.33%	7,400 $9,000
Q3 2020 Oct 27, 2020	SELL	$28.28 - $53.6 $14,140 - $26,800	-500 Reduced 17.24%	2,400 $8,000
Q2 2020 Jul 22, 2020	BUY	$27.89 - $47.86 $36,257 - $62,218	1,300 Added 81.25%	2,900 $17,000
Q1 2020 May 07, 2020	BUY	$12.04 - $60.2 $19,264 - $96,320	1,600 New	1,600 $11,000

219

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.